Revolution climbs after report of Merck's up to $32 bln buyout talks

Revolution Medicines

09/01/2026 11:21

** Shares of Revolution Medicines RVMD.O rise 15% to $123.49 premarket

** Merck MRK.N is in talks to buy Revolution in a deal worth up to $32 bln, FT reported on Thursday

** Analysts see over $10 billion in potential sales from Revolution’s RAS inhibitor portfolio by 2035

** FT report came a day after AbbVie ABBV.N denied a WSJ report that it was in advanced talks to acquire Revolution

** RVMD shares have surged about 34% since the WSJ report, adding about $5.3 billion to its market value, which stood near $20.8 billion, as of last close

** RVMD recently traded at -16.7 times fwd earnings, compared to its five-year avg of -9.8, per LSEG data

** RVMD gained more than 82% in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))